好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Earliest Description of Endemic Amyotrophic Lateral Sclerosis (ALS) in Kii Peninsula in Japan as “Endemic Paraplegia of Koza in Kii” Published in 1689 Honcho Koji Innen Shu
History of Neurology
P2 - Poster Session 2 (11:45 AM-12:45 PM)
1-013

 Review elements of evidence supporting 17th century description of endemic ALS in Kii peninsula reported by Yoshino Yase in Kuzuhara 2021.

 

Kumano Province (Muro County of Kii) was regarded as the Holy Land of Japanese Shintoism since the 7th century containing three Grand Shrines of Japanese Shintoism (Taisha). Yoshino Yase identified a book from the 17th century titled “Honcho Koji Innen Shu” that was a collection (“Shu”) of tales and legends in the past (“Koji”) which had been handed down by oral history in Japan (“Honcho”).  Each story is accompanied by a coda “Innen” - the karma in Buddhism that describes the consequence resulting from the reported event. The book is woodblock-printed with Chinese ink on Japanese paper in kanji (Chinese character) containing 156 short mysterious stories and legends collected in the 17th century from all over Japan. Each story usually consists of two parts: first, a presentation of real-looking but mysterious events, and second, comments of the writer and explanation by the karma (its effect and cause) to be learned from the story.

The 92nd story expounds the clinical report that Kinbei Yamamoto developed, without fever, motor paraplegia of subacute onset and of chronic course without remission or recovery named “paraplegia of Koza.” Further description included endemic paraplegia among inhabitants of Koza Village for generations” resembling   endemic ALS in the Kozagawa focus for generations.

Elements of geography, culture and history support that “mysterious paraplegia of Koza” existed as the same disorder similar to Kii ALS of the hyperendemic focus of Kozagawa at present.

No visual depiction of the muscle mass in reported cases are presented.  The slow progression and repeated occurrence in later generations increases the likelihood that the reported cases may have been present for two centuries prior to the first modern reports.

Authors/Disclosures
Benjamin R. Brooks, MD, FAAN (Clinical Trials Planning LLC)
PRESENTER
Dr. Brooks has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Mitsubishi Tanabe Pharma America. Dr. Brooks has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Medicinova. Dr. Brooks has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Brooks has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AB Science. Dr. Brooks has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Ionis. Dr. Brooks has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Mitsubishi Tanabe Pharma America. The institution of Dr. Brooks has received research support from Mitsubishi TanabePharma America. Dr. Brooks has received personal compensation in the range of $0-$499 for serving as a Member Annual Surveillance Committee CDC National ALS Registry with Center for Disease Control Agency Toxic Substances Disease Registry. Dr. Brooks has a non-compensated relationship as a Member ALS Quality Measures Subcommittee with 好色先生 that is relevant to AAN interests or activities.